GE HealthCare Technologies (GEHC) 2024 Wells Fargo Healthcare Conference summary

Strategic progress and operational highlights

• Significant investments in innovation and R&D, with new processes like global product planning driving a robust pipeline.

• Commercial teams reorganized, resulting in strong growth in key regions and business lines, especially in the US and PDX.

• Lean transformation initiatives have improved gross margins and EBIT, with a focus on cost, safety, quality, and delivery.

• Guidance was lowered mid-year due to China market volatility, but teams are navigating the environment effectively.

• Forward-looking focus on innovation, commercial execution, and cost transformation to drive future growth.

Financial outlook and guidance

• Q3 guidance implies ~1% growth, with a step-up expected in Q4, supported by a strong backlog and easier comps.

• Guidance reduction of $400–$600 million was entirely due to China market uncertainty.

• Margins expanded in H1 2024 despite flat sales, driven by cost productivity and pricing initiatives.

• Margin expansion expected to continue, aided by incremental volume, price, and absence of prior year one-time R&D costs.

• Hospital capital environment remains attractive outside China, with strong order performance and improved hospital profitability.

China market dynamics

• China stimulus rollout is slower than previous cycles, with a longer pre-tender to order process.

• Long-term outlook for China remains positive, with expectations of pent-up demand benefiting future years.

• Guidance was reduced to avoid speculation on stimulus impact; future growth potential remains.

• Government commitment to healthcare infrastructure expansion is clear, despite current delays.